Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2011 Earnings Results

Arrowhead Pharmaceuticals Beats on EPS, Stock Down 0.31%

Arrowhead Pharmaceuticals reported a narrower loss than expected with an EPS of $-0.01, which was a positive surprise. However, the stock reacted negatively, declining by 0.31%. The lack of revenue figures and management commentary may have contributed to investor uncertainty.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.01	N/A	+50.00%
Revenue	—	N/A	—

Management

Management commentary

Tone: Unknown

No transcript is on record for this earnings call, so the analysis is based solely on numerical results.

Arrowhead Pharmaceuticals Beats on EPS, Stock Down 0.31%

Key numbers

Management commentary

Arrowhead Pharmaceuticals, Inc.

More earnings this week

Arrowhead Pharmaceuticals Beats on EPS, Stock Down 0.31%

Key numbers

Management commentary